Efficacy and Safety of Tianzhi Granule in Mild to Moderate Vascular Dementia

Vascular Dementia Clinical Trial

Official title:

A Phase III, Multicenter, Randomized, Double-blind, Positive /Placebo Controlled, Parallel, Three Arms Study of Tianzhi Granule in Mild to Moderate Vascular Dementia

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT02453932
• Other study ID #: 2012ZX09104-203
• Status: Completed
• Phase: Phase 3
• Start date: October 2013
• Est. completion date: May 2017

Study information

• Verified date: January 2020
• Source: Dongzhimen Hospital, Beijing
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This ongoing study aimed to evaluate the efficacy and safety of Tianzhi granule in mild to moderate vascular dementia in a more reasonable design.

Description:

This study is a 24-weeks, multicenter, randomized, double-blind, double- placebo, parallel controlled phase III trial being carried out in 23 centers around China. The study population includes mild to moderate VaD patients (planned a total of 630) aged 45-85 in both gender. Participants will be randomly allocated to TZK (15g/d) and placebo identified to donepezil, donepezil (5mg/d) and placebo identified to TZK, or placebo identified to TZK and placebo identified to donepezil for a 24-weeks double-blind treatment period . The primary outcome measure is change from baseline in the Vascular Dementia Assessment Scale-Cognitive Subscale and Clinician's Interview-Based Impression of Change-Plus carer Interview. The secondary outcomes are changes from baseline in the Mini-Mental State Examination, Activity of Daily Living Scale, Clock Drawing Test, Trail Making Test and Neuropsychiatric Inventory. Safety is being assessed by observing side effects and adverse reaction during the entire treatment period. Statistical analysis will be conducted according to per-protocol population and intend-to-treat population and the safety will be analyzed in safety set.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 543
• Est. completion date: May 2017
• Est. primary completion date: May 2017
• Accepts healthy volunteers: No
• Gender: All
• Age group: 45 Years to 85 Years

Eligibility

Inclusion Criteria:

• Inpatients and outpatients meeting the diagnostic criteria probable VaD established according to the Diagnostic and Statistical Manual of Mental Disorders (fourth edition) (DSM-?) and the National Institute of Neurological Disorders and Stroke and the Association Internationale pour la Recherche et l'Enseignement en Neurosciences (NINDS-AIREN)were eligible to participate,

• diagnosis of mild to moderate vascular dementia;

• Chinese-speaking patients aged =45 and=85 years old in both gender;

• weighing between 45 and 90kg;

• fully conscious;

• MMSE score of=26 and =14;

• HIS score of =7;

• adequate vision and hearing ability to complete all study tests;

• with a stable caregiver.

Exclusion Criteria:

Patients will be excluded from the enrollment if they meet any of the followings:

• a medical history of other dementia types, like Alzheimer's disease, Parkinson's disease dementia, Huntington disease, Normal pressure hydrocephalus, et al;

• major depression (HAMD for 17 items>17) or psychotic disorder;

• acute stage of cerebral hemorrhage or subarachnoid hemorrhage;

• hypothyroidism;

• drug or alcohol abuse;

• epilepsy history; myasthenia gravis history;

• severe cardiovascular disease(severe arrhythmia with heart rate=100 or=60 times per min, left bundle branch block, myocardial infarction within 3 months, systolic pressure=180mmHg or =90mmHg);

• severe liver or kidney dysfunction (alanine aminotransferase>60 IU/L, aspartate transaminase>60 IU/L or serum creatinine >266µmol/L);

• severe asthma or chronic obstructive pulmonary disease;

• gastrointestinal tract obstruction or severe peptic ulcer; glaucoma;

• administration of cholinesterase inhibitors, memantine or nimodipine in the last month;

• use of sympathomimetic agent, antihistamine drug, antianxiety drugs or tranquilizer within 48h before assessment;

• use of antipsychotic drugs within 72h before assessment;

• participation in other clinical trials; allergic history to any type of medication used in this study.

Related Conditions & MeSH terms

• Dementia
• Dementia, Vascular
• Vascular Dementia

Intervention

Drug:
• Tianzhi granule and placebo identified to donepezil
1 pack Tianzhi granule (5g), 3 times per day and placebo identified to donepezil, 1 pill per day for 24 weeks
• Donepezil and placebo identified to Tianzhi granule
donepezil 5mg per day and placebo identified to Tianzhi granule (5g, 3 times per day) for 24 weeks
• Placebo
placebo identified to Tianzhi granule (5g, 3 times per day) and placebo identified to donepezil ,1 pills per day for 24 weeks

Locations

Country	Name	City	State
China	Dongzhimen Hospital,Beijing University of Chinese Medicine	Beijing	Beijing

Sponsors (1)

Lead Sponsor	Collaborator
Dongzhimen Hospital, Beijing

Country where clinical trial is conducted

China, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Changes of Vascular Dementia Assessment Scale-Cognitive Subscale(VADAS-cog) from baseline after 24 weeks' intervention	Cognition : VaDAS-cog is a revision of the ADAS-cog to be a better measure in vascular conditions. The original ADAS-cog developed by Rosen et al., measures cognitive performance by combining ratings of 11 items. The cognitive domains mainly addressed by ADAS-cog are memory (short term), language, ability to orientate (reflects memory), construction/planning of simple designs and performance. In addition to ADAS-cog, the VaDAS-cog comprises additional frontal lobe tests reflecting attention, working memory, executive function, and verbal fluency.The VADAS-cog will conducted at baseline, 4weeks, 12weeks, 24weeks	week 0, 4, 12, 24
Primary	Changes of Clinician's Interview-Based Impression of Change-Plus carer Interview(CIBIC-plus) from baseline after 24 weeks' intervention	Overall clinical response: CIBIC-plus is a 7-point scale which provides an index of clinically important change for dementia patients. It is a global measure of detectable change in concentration, orientation, memory, language, behavior, initiative and activities of daily living, usually requiring separate interviews with patients and caregivers,the CIBIC-plus will be conducted at baseline, 4weeks, 12weeks, 24weeks	week 0, 4, 12, 24
Secondary	Changes of Mini-Mental State Examination(MMSE) from baseline after 24 weeks' treatment	Global cognition will be assessed by the MMSE,which will be conducted at baseline, 4weeks, 12weeks, 24weeks.	week 0, 4, 12, 24
Secondary	Changes of Activity of Daily Living Scale(ADL) from baseline after 24 week's intervention	Function:The ADL mainly used to measure the basic activities of daily living (or self-care) and the instrumental activities of daily living. The ADL scale can be divided to Physical Self-Maintenance Scale (PSMS) and the instrumental activities of daily living (IADL). The PSMS relate to physical activities, such as toileting, mobility, dressing and bathing , and the IADL contains 8 items ,such as shopping, cooking, doing laundry, handling finances, using telephone, mode of transportation, responsibility for own medication and housekeeping.The ADL wil be conducted baseline, 4weeks, 12weeks, 24weeks	week 0, 4, 12, 24
Secondary	Changes of Clock Drawing Test(CDT) from baseline after 24 week's intervention	Executive function and Visuospatial function : the CDT scale will be conducted at baseline, 4weeks, 12weeks, 24weeks.	week 0, 4, 12, 24
Secondary	Changes of Trail Making Test (TMT) from baseline after 24 week's intervention	Executive function: The TMT scale will be conducted at baseline, 4weeks, 12weeks, 24weeks.	week 0, 4, 12, 24
Secondary	Changes of Neuropsychiatric Inventory(NPI) from baseline after 24 weeks' intervention	Changes in psychological symptom: NPI is used throughout the study to assess changes in psychological symptom,the NPI will be conducted at baseline, 4 weeks, 12 weeks, 24 weeks.	week 0, 4, 12, 24